Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “dupilumab” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 62
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 62 pipeline programs matching "dupilumab" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

62 results for “dupilumab” Back to intelligence hub

Search results

Page 3 of 3
  1. Dupilumab

    Regeneron UK Limited

    Moderate-to-Severe Atopic Dermatitis

    approved small molecule completed

    2 trials
  2. Dupilumab

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease

    approved small molecule active

    1 trial
  3. Dupilumab

    Regeneron UK Limited

    Atopic Dermatitis (AD)

    approved small molecule terminated

    2 trials
  4. Dupilumab

    Regeneron UK Limited

    Eosinophilic Esophagitis

    approved small molecule active

    4 trials
  5. Dupilumab

    Regeneron UK Limited

    Dermal Hypersensitivity Reaction

    approved small molecule completed

    1 trial
  6. Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

    Regeneron UK Limited

    Eosinophilic Esophagitis (EoE)

    approved small molecule active

    1 trial
  7. Dupilumab Injectable Product

    Regeneron UK Limited

    Asthma

    approved small molecule active

    1 trial
  8. Dupilumab Only Product

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule active

    1 trial
  9. Dupilumab Prefilled Syringe

    Regeneron UK Limited

    Nasal Polyps

    approved small molecule active

    1 trial
  10. Dupilumab SAR231893

    Regeneron UK Limited

    Atopic Dermatitis

    approved small molecule completed

    1 trial
  11. Dupilumab SAR231893

    Regeneron UK Limited

    Chronic Rhinosinusitis With Nasal Polyps

    approved small molecule completed

    1 trial
  12. Dupilumab SAR231893

    Regeneron UK Limited

    Dermatitis Atopic

    approved small molecule completed

    2 trials
  13. dupilumab

    Regeneron UK Limited

    Severe Atopic Dermatitis (AD)

    approved small molecule terminated

    1 trial
  14. dupilumab

    Regeneron UK Limited

    Chronic Obstructive Pulmonary Disease (COPD)

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.